USPTO serial 79420853
AUTOLUS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 13, 2026
- Examiner
- HARMON, RAYMOND E
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with AUTOLUS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Rebecca Liebowitz
Rebecca Liebowitz Venable LLPP.O. Box 34385Washington, DC 20043-9998United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medical and veterinary preparations for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases for therapeutic purposes; pharmaceutical preparations for cell therapy; pharmaceutical preparations for gene therapy for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; pharmaceutical preparations for cancer therapies; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for treatment of cancer comprising chimeric antigen receptors (CAR) and therapeutic preparations thereof; antibodies for medical purposes; pharmaceutical preparations for genetically modifying human or animal cells for medical purposes, in particular viral vectors; pharmaceutical preparations of blood extracted from humans or animals which have been adapted for therapeutic purposes for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; pharmaceutical preparations for use in the treatment of cancer; pharmaceutical preparations for use in the treatment of autoimmune diseases; biological preparations for the treatment of cancer; biological preparations for use in the treatment of autoimmune diseases; pharmaceutical and biological preparations for immunotherapy, in particular T cell therapy; vaccines | ACTIVE | — |
| 040 | Custom manufacture of therapeutic drugs, namely cell therapies, preparations to treat autoimmune diseases, cancer therapies and cancer vaccines | ACTIVE | — |
| 042 | Scientific and technological services and research and design relating thereto, namely, medical research, scientific research, analysis and testing in the field of human and animal cell, gene and cancer therapies, pharmaceutical product development, research and development of new products; industrial analysis and research services in the field of cell, gene and cancer therapies; medical and veterinary research services, in particular in the field of the manipulation of cells within a laboratory or research facility to enable the cells to be used for therapeutic purposes; scientific research in the development of autoimmune diseases and new cancer therapies; scientific research in human and animal cell therapy; scientific research in human and animal gene therapy; scientific research into vaccines, in particular personalised cancer vaccines; scientific research into vectors and preparations for manipulating and adapting human and animal cells; consultancy relating to all the aforesaid services | ACTIVE | — |
| 044 | Medical services; veterinary services; medical services for the extraction of human and animal cells from patients; medical services, namely, manipulation of human and animal cells for therapeutic purposes; medical services, namely, reinsertion of cells into human and animal patients; medical and veterinary services, namely, providing advice and consultancy in the field of medical and veterinary therapies; medical and veterinary services, namely, providing advice and consultancy in the field of autoimmune diseases, cancer therapies and cancer vaccines | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Autolus Limited
- Other trademarks owned by Autolus Limited
- Other trademarks owned by Autolus Limited
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named AUTOLUS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 17, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Sep 2, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 2, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Aug 6, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 19, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 19, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 13, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 13, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 13, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 25, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 25, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 19, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 27, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 27, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 27, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 27, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 12, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 21, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 21, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 18, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 17, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 9, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 4, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 4, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 3, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |